X
MRVI icon

Xponance’s Maravai LifeSciences MRVI Stock Holding History

Xponance’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67K Buy
+10,733
New +$46.3K ﹤0.01% 1761
2024
Q2 		– Sell
-10,297
Closed -$89.3K – 1349
2024
Q1 		$89.3K Sell
10,297
-706
-6% -$4.78K ﹤0.01% 1246
2023
Q4 		$72.1K Buy
11,003
+391
+4% +$2.53K ﹤0.01% 1223
2023
Q3 		$106K Buy
10,612
+88
+0.8% +$966 ﹤0.01% 1163
2023
Q2 		$131K Sell
10,524
-5,009
-32% -$67.6K ﹤0.01% 1178
2023
Q1 		$218K Buy
15,533
+1,070
+7% +$15.4K ﹤0.01% 1109
2022
Q4 		$207K Buy
14,463
+1,435
+11% +$22.6K ﹤0.01% 1116
2022
Q3 		$333K Buy
13,028
+190
+1% +$4.77K 0.01% 966
2022
Q2 		$365K Buy
12,838
+641
+5% +$20.3K 0.01% 960
2022
Q1 		$430K Sell
12,197
-540
-4% -$18.1K 0.01% 945
2021
Q4 		$534K Buy
12,737
+1,207
+10% +$48.9K 0.01% 875
2021
Q3 		$566K Buy
11,530
+2,922
+34% +$143K 0.01% 832
2021
Q2 		$359K Buy
+8,608
New +$334K 0.01% 1026

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Xponance's MRVI Position: Q2 2026 in Review

Xponance opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 10,733 shares worth $67K. The stake represents ﹤0.01% of the portfolio and ranks #1761 among its holdings. This is a return to the name: Xponance previously reported a position in MRVI as recently as Q1 2024.

Xponance first reported a position in MRVI in Q2 2021 and has held it in 13 quarters since. The position peaked at $566K in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Xponance held 10,733 shares of Maravai LifeSciences worth $67K as of Q2 2026.
  • Maravai LifeSciences was a new Xponance position in Q2 2026.
  • Maravai LifeSciences made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1761 holding.
  • Xponance first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 13 quarters since.
  • Xponance's Maravai LifeSciences position peaked at $566K in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.